CM326 not checked

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Keymed Biosciences Co.Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
13 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Placebo of CM326, administered subcutaneously, once every 4 weeks”In the company’s words, NCT07420257 on ClinicalTrials.gov
Tested for
Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
Main trialPhase 3
“This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and I immumogenicity\[c2.1\] of CM326 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).The study consists of four periods, including an up to 4-week screening/run-in period, a 24-week double-blind randomized treatment period, a 28-week open-label treatment period, and an 8-week safety follow-up period.”In the company’s words, NCT07420257 on ClinicalTrials.gov

Other drugs for Chronic Rhinosinusitis With Nasal Polyps

All 3 drugs for Chronic Rhinosinusitis With Nasal Polyps

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Oct 2028 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Phase 3Recruiting 31 Dec 2028 A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
Phase 2Recruiting 1 Jul 2027 A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 1Not yet recruiting 1 Oct 2026 A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects
Phase 2Unknown 30 Dec 2023 The Study of CM326 in Moderate-to-severe Atopic Dermatitis
Phase 2Unknown 28 Mar 2024 The Study of CM326 in Adult Subjects With Atopic Dermatitis
Phase 2Unknown Jan 2025 A Study of CM326 in Subjects With Moderate to Severe Asthma
Phase 2Unknown 30 Jun 2026 Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Phase 1/2Unknown Jan 2023 The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
Phase 1/2Completed 29 Mar 2024 A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase 1Completed 28 Sep 2021 Single Ascending Dose Study of CM326 in Healthy Volunteers
Phase 1Completed 11 Oct 2022 A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects
Phase 1Completed 4 Oct 2023 Study of CM326 Injection in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CM326

Following is part of Solo: you see every change to CM326 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in